American Assets Trust is a self-administered real estate investment trust that owns, operates, acquires and develops retail, office, multifamily and mixed-use properties in Southern California, Northern California, Oregon, Washington, Texas and Hawaii. The company operates in four segments: Retail, which primarily include rental of retail space and other tenant services, including tenant reimbursements, parking and storage space rental; Office, which primarily include rental of office space and other tenant services; Multifamily, which include rental of apartments and other tenant services; and Mixed-use, which include rental of retail space and other tenant services.

Aptevo Therapeutics is a biotechnology company focused on oncology (cancer) and hematology (blood disease) therapeutics. The company's core technology is the ADAPTIR? (modular protein technology) platform. The company's product candidates include: APVO436, an ADAPTIR bispecific immunotherapeutic protein targeting CD123, a cell surface receptor expressed on several hematological malignancies and CD3, a component of the T-cell receptor; APVO210, an anti-inflammatory molecule engineered using the company's ADAPTIR platform technology; and ALG.APV-527, a bispecific antibody candidate, featuring a mechanism of action designed to target 4-1BB (CD137) and 5T4, a tumor antigen overexpressed in various types of cancer.

Athenex is a biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer. The company has three platforms: its Oncology Innovation Platform, dedicated to the research and development of its proprietary drugs; its Commercial Platform, focused on the sales and marketing of its specialty drugs and the market development of its proprietary drugs; and its Global Supply Chain Platform, dedicated to providing a supply of active pharmaceutical ingredients for its clinical and commercial efforts. The company's clinical pipeline includes: Orascovery, Src Kinase inhibition, T-cell Receptor-engineered T-cells, and arginine deprivation therapy.

Cincinnati Financial is a holding company. Through its subsidiaries, the company is engaged in property casualty insurance. The company's market property casualty insurance group includes its subsidiaries, The Cincinnati Casualty Company and The Cincinnati Indemnity Company, which write business, homeowner and auto policies. The company's subsidiary, The Cincinnati Insurance Company conducts the business of the company's reinsurance assumed operations. Other subsidiaries include: The Cincinnati Life Insurance Company, which provides life insurance policies and fixed annuities; and The Cincinnati Specialty Underwriters Insurance Company, which provides excess and surplus lines insurance products.

Five Prime Therapeutics is a clinical-stage biotechnology company focused on discovering and developing protein therapeutics. The company's key product candidates are: FPA150, which is a CD8 T cell checkpoint inhibitor antibody that targets B7-H4 that it is studying in a clinical trial in multiple cancers; FPT155, which is a soluble CD80 fusion protein that enhances co-stimulation of T cells through CD28 that the company is studying in a clinical trial in multiple cancers; and Cabiralizumab (FPA008) is an antibody that the company and its partner Bristol-Myers Squibb Company, or BMS, are studying in clinical trials in multiple cancers in combination with BMS's PD-1 immune checkpoint inhibitor, Opdivo? (nivolumab).

GlycoMimetics is a clinical stage biotechnology company focused on the discovery and development of glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a main role. The company is developing uproleselan, a specific E-selectin inhibitor, to be used in combination with chemotherapy to treat patients with acute myeloid leukemia and other hematologic cancers. The company is also developing an additional drug candidate, GMI-1359, that simultaneously targets both E-selectin and a chemokine receptor known as CXCR4.

Golub Capital BDC is registered as an externally managed, closed-end, non-diversified management investment company. The company makes investments primarily in one stop (a loan that combines characteristics of first lien senior secured loans and second lien or subordinated loans) and other senior secured loans of middle-market companies that are, in most cases, sponsored by private equity firms. The company's investment objective is to generate existing income and capital appreciation by investing primarily in one stop and other senior secured loans of United States middle-market companies.

Heartland Financial USA is a multi-bank holding company. The company conducts a community banking business through community banks (collectively, the Banks). The principal business of the company's Banks consists of making loans to and accepting deposits from businesses and individuals. The company's Banks provide commercial and retail banking in their communities. The company's lending and investment activities are funded primarily by core deposits. Deposit products include checking and other demand deposit accounts, Negotiable Order of Withdrawal accounts, savings accounts, money market accounts, certificates of deposit, individual retirement accounts, health savings accounts and other time deposits.

Safety Insurance Group is a holding company. Through its subsidiaries, the company is a provider of private passenger, commercial automobile and homeowners insurance in Massachusetts. The company's product lines include: Private Passenger Automobile, which provides coverage for bodily injury and property damage to others, no-fault personal injury coverage for the insured/insured's car occupants, and physical damage coverage for an insured's own vehicle for collision or other perils; Commercial Automobile, which provides insurance for commercial vehicles used for business purposes; and Inland Marine, which provides inland marine coverage as an endorsement for all homeowners and business owner policies.